Compare NEULAND LABS with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS PIRAMAL ENTERPRISES NEULAND LABS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 59.2 -40.8 - View Chart
P/BV x 4.5 1.4 325.9% View Chart
Dividend Yield % 0.1 1.7 4.8%  

Financials

 NEULAND LABS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
PIRAMAL ENTERPRISES
Mar-19
NEULAND LABS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs7543,303 22.8%   
Low Rs2471,797 13.8%   
Sales per share (Unadj.) Rs594.5716.5 83.0%  
Earnings per share (Unadj.) Rs12.679.7 15.8%  
Cash flow per share (Unadj.) Rs37.0107.9 34.3%  
Dividends per share (Unadj.) Rs2.0028.00 7.1%  
Dividend yield (eoy) %0.41.1 36.4%  
Book value per share (Unadj.) Rs553.41,477.5 37.5%  
Shares outstanding (eoy) m12.83184.45 7.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.83.6 23.7%   
Avg P/E ratio x39.632.0 123.8%  
P/CF ratio (eoy) x13.523.6 57.2%  
Price / Book Value ratio x0.91.7 52.4%  
Dividend payout %15.835.1 45.1%   
Avg Mkt Cap Rs m6,421470,292 1.4%   
No. of employees `0001.37.8 16.4%   
Total wages/salary Rs m1,23622,504 5.5%   
Avg. sales/employee Rs Th5,949.416,899.4 35.2%   
Avg. wages/employee Rs Th963.82,877.7 33.5%   
Avg. net profit/employee Rs Th126.41,879.9 6.7%   
INCOME DATA
Net Sales Rs m7,627132,153 5.8%  
Other income Rs m393,128 1.2%   
Total revenues Rs m7,666135,281 5.7%   
Gross profit Rs m1,01966,290 1.5%  
Depreciation Rs m3135,202 6.0%   
Interest Rs m21644,097 0.5%   
Profit before tax Rs m52920,119 2.6%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3678,611 4.3%   
Profit after tax Rs m16214,701 1.1%  
Gross profit margin %13.450.2 26.6%  
Effective tax rate %69.442.8 162.1%   
Net profit margin %2.111.1 19.1%  
BALANCE SHEET DATA
Current assets Rs m5,152122,742 4.2%   
Current liabilities Rs m3,576310,810 1.2%   
Net working cap to sales %20.7-142.3 -14.5%  
Current ratio x1.40.4 364.8%  
Inventory Days Days10523 455.5%  
Debtors Days Days9139 234.0%  
Net fixed assets Rs m3,969116,904 3.4%   
Share capital Rs m129369 35.0%   
"Free" reserves Rs m6,971272,161 2.6%   
Net worth Rs m7,100272,530 2.6%   
Long term debt Rs m774270,196 0.3%   
Total assets Rs m12,310856,261 1.4%  
Interest coverage x3.51.5 237.1%   
Debt to equity ratio x0.11.0 11.0%  
Sales to assets ratio x0.60.2 401.5%   
Return on assets %3.16.9 44.7%  
Return on equity %2.35.4 42.3%  
Return on capital %9.512.4 76.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,18715,200 34.1%   
Fx outflow Rs m1,5934,889 32.6%   
Net fx Rs m3,59410,312 34.9%   
CASH FLOW
From Operations Rs m573-115,975 -0.5%  
From Investments Rs m-487-8,265 5.9%  
From Financial Activity Rs m-55107,525 -0.1%  
Net Cashflow Rs m33-16,650 -0.2%  

Share Holding

Indian Promoters % 36.3 52.9 68.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 4.0 1,593.3%  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 16.5 386.2%  
Shareholders   12,705 93,274 13.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare NEULAND LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Dives Over 1,100 Points, Dow Futures Down by 119 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Apr 19, 2021 03:16 PM

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 8-QTR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS